Pharmaceuticals, Biotechnology and Life Sciences
Nevakar, ophthalmology specialist pharmaceutical company has entered into a $17.5 million product financing agreement with an affiliate of H.I.G. Capital Partners, L.P. for the continued development of five differentiated, sterile injectable products.
Novartis’ company Avexis said that it’s Phase 1/2 Srong study for intrathecal (IT) administration of AVXS-101, showed that patients aged 2 to 5, with spinal muscular atrophy (SMA) Type 2 achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold, at a mean duration of follow-up time of 9.3 months.
Swiss-based biopharmaceutical drugmaker Debiopharm presented results for its novel IAP antagonist Debio 1143 from phase two trial, for high-risk Head and Neck cancer patients, which met its primary goal of increasing treatment efficacy compared to CRT and placebo.
Azelis, a leading distributor of specialty chemicals and food ingredients, will acquire Orkila, the top specialty chemicals and food ingredients distributor throughout Africa and the Middle East.
Swedish Orphan Biovitrum (Sobi) said Monday it will Dova Pharmaceuticals for an upfront payment of $27.50 per share in cash and, one non-tradeable Contingent Value Right (CVR), with an additional $1.50 for shareholders upon approval of Doptelet for use in Chemotherapy-Induced Thrombocytopenia (CIT) by the US Food and Drug Administration (FDA).
FDA has approved Invokana (canagliflozin) to treat diabetic kidney disease (DKD) and reduce the risk of hospitalization for heart failure in patients with type 2 diabetes (T2D) and DKD, which is the only diabetes medicine indicated to slow the progression of diabetic nephropathy (also known as DKD) and reduce the risk of hospitalization for heart failure in patients with T2D and DKD.
Alvotech said in a Monday press release it has appointed Joseph Edward McClellan as its new Chief Scientific Officer, who will be leading the company’s R&D functions, with overall responsibility for bringing products to market through its pipeline and overseeing R&D operations across Alvotech’s sites in Reykjavik, Julich, Hanover and Zurich.
Novartis will present results from its trial designated Mnaleesa-3, which showed that ribociclib branded as Kisqali has achieved statistically significant improvement in overall survival (OS), which is – according to Novartis – the only CDK4/6 inhibitor to demonstrate positive overall survival in two pivotal Phase III trials — consistently demonstrating approximately 30% reduction in the risk of death.
Elevar Therapeutics presented a study at ESMO, showing the potential of rivoceranib to treat patients with late-stage gastric cancer, which was is the first multinational phase 3 study after rivoceranib’s approval in China, said Dr. Steven Norton, Elevar Therapeutics’ Vice President of Clinical Development.
Researchers presented results from Adlai Nortye’s investigational, potentially first in class oral EP4 antagonist, two dose levels of AN0025 in combination with the standard of care for locally advanced rectal cancer where primary resection without chemoradiotherapy is unlikely to achieve clear margins as defined by MRI at ESMO.